ATE137806T1 - Verfahren zur identifizierung von bakterien - Google Patents
Verfahren zur identifizierung von bakterienInfo
- Publication number
- ATE137806T1 ATE137806T1 AT89909671T AT89909671T ATE137806T1 AT E137806 T1 ATE137806 T1 AT E137806T1 AT 89909671 T AT89909671 T AT 89909671T AT 89909671 T AT89909671 T AT 89909671T AT E137806 T1 ATE137806 T1 AT E137806T1
- Authority
- AT
- Austria
- Prior art keywords
- antisense oligonucleotide
- operon
- macromolecular synthesis
- stranded dna
- single stranded
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 5
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 5
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 5
- 230000015572 biosynthetic process Effects 0.000 abstract 4
- 238000003786 synthesis reaction Methods 0.000 abstract 4
- 108020004414 DNA Proteins 0.000 abstract 3
- 102000053602 DNA Human genes 0.000 abstract 3
- 108020004682 Single-Stranded DNA Proteins 0.000 abstract 3
- 108020004999 messenger RNA Proteins 0.000 abstract 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21513588A | 1988-07-05 | 1988-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE137806T1 true ATE137806T1 (de) | 1996-05-15 |
Family
ID=22801802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89909671T ATE137806T1 (de) | 1988-07-05 | 1989-06-30 | Verfahren zur identifizierung von bakterien |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0424473B1 (de) |
| JP (1) | JPH03505672A (de) |
| AT (1) | ATE137806T1 (de) |
| AU (1) | AU4180889A (de) |
| CA (1) | CA1340796C (de) |
| DE (1) | DE68926455T2 (de) |
| WO (1) | WO1990000624A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5294533A (en) * | 1988-07-05 | 1994-03-15 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
| FR2651130B1 (fr) * | 1989-08-23 | 1991-12-13 | Roussel Uclaf | Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques. |
| US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
| US5384261A (en) * | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| CA2126979A1 (en) * | 1991-12-31 | 1993-07-22 | Eliezer Rapaport | Antiparasitic oligonucleotides active against drug resistant malaria |
| WO1994025598A2 (en) * | 1993-04-26 | 1994-11-10 | University Of Victoria Innovation And Development Corporation | Methods and compositions for salmonella-based vaccines |
| AU7019794A (en) * | 1993-05-26 | 1994-12-20 | Genta Incorporated | Oligomer conjugates and their use |
| US6440660B1 (en) | 1995-11-17 | 2002-08-27 | Hybridon, Inc. | Oligonucleotide mediated reversal of drug resistance |
| US6096499A (en) * | 1996-03-22 | 2000-08-01 | Geron Corporation | Mammalian DNA primase screen and activity modulating agents |
| WO1998014567A2 (en) * | 1996-10-01 | 1998-04-09 | Advanced Research & Technology Institute | Methods and compositions for inhibiting bacterial growth |
| US6300318B1 (en) * | 1997-09-16 | 2001-10-09 | Peter E. Nielsen | Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor |
| WO1999067400A1 (en) | 1998-06-24 | 1999-12-29 | Musc Foundation For Research Development | Tissue-specific and target rna-specific ribozymes |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| JP2002541822A (ja) | 1999-04-14 | 2002-12-10 | エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント | 組織特異的および病原体特異的毒性物質ならびにリボザイム |
| WO2001012803A2 (en) * | 1999-08-17 | 2001-02-22 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for restoring antibiotic susceptibility in glycopeptide-resistant enterococcus |
| US10400291B2 (en) | 2014-06-27 | 2019-09-03 | The Regents Of The University Of Michigan | Method for bacterial species identification and strain typing |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358535A (en) * | 1980-12-08 | 1982-11-09 | Board Of Regents Of The University Of Washington | Specific DNA probes in diagnostic microbiology |
| ATE75483T1 (de) * | 1981-10-23 | 1992-05-15 | Molecular Biosystems Inc | Oligonukleotides heilmittel und dessen herstellungsverfahren. |
| US4740463A (en) * | 1984-04-13 | 1988-04-26 | Massachusetts Institute Of Technology | Methods and artificial genes for antagonizing the function of an oncogene |
| US5024943A (en) * | 1985-11-07 | 1991-06-18 | Gist-Brocades | Regulatory region cloning and analysis plasmid for bacillus |
| FR2596774B1 (fr) * | 1986-04-04 | 1988-07-22 | Pasteur Institut | Sondes oligonucleotidiques et procedes pour la detection par hybridation des acides nucleiques de bacteries et autres etres vivants |
| US4806463A (en) * | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| US4801540A (en) * | 1986-10-17 | 1989-01-31 | Calgene, Inc. | PG gene and its use in plants |
-
1989
- 1989-06-30 AT AT89909671T patent/ATE137806T1/de not_active IP Right Cessation
- 1989-06-30 DE DE68926455T patent/DE68926455T2/de not_active Expired - Fee Related
- 1989-06-30 EP EP89909671A patent/EP0424473B1/de not_active Expired - Lifetime
- 1989-06-30 AU AU41808/89A patent/AU4180889A/en not_active Abandoned
- 1989-06-30 WO PCT/US1989/002884 patent/WO1990000624A1/en not_active Ceased
- 1989-06-30 JP JP1509036A patent/JPH03505672A/ja active Pending
- 1989-07-05 CA CA000604846A patent/CA1340796C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU4180889A (en) | 1990-02-05 |
| EP0424473B1 (de) | 1996-05-08 |
| WO1990000624A1 (en) | 1990-01-25 |
| DE68926455T2 (de) | 1996-10-31 |
| CA1340796C (en) | 1999-10-19 |
| JPH03505672A (ja) | 1991-12-12 |
| EP0424473A1 (de) | 1991-05-02 |
| DE68926455D1 (de) | 1996-06-13 |
| EP0424473A4 (en) | 1992-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2048450A1 (en) | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria | |
| DE68926455D1 (de) | Verfahren zur identifizierung von bakterien | |
| BR9206049A (pt) | Composto, processos para preparar o composto, para o reconhecimento específico por sequência de um polinucleotídio de filamento duplo, para modular a expressão de um gene em um organismo, para tratar as condições associadas com produção de proteínas indesejada em um organismo, para induzir a degradação de DNA ou RNA em células de um organismo e para exterminar células ou vírus e composição farmacêutica | |
| DE58908694D1 (de) | Oligonucleotidbank und verfahren zur dna-sequenzierung. | |
| ATE515510T1 (de) | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide | |
| DE69729179D1 (de) | Kohlenhydratmodifizierte luckenhafte oligonukleotide | |
| EP0828849A4 (de) | Oligonukleotidliganden mit hoher affinität für wachstumsfaktoren | |
| NO930515L (no) | Oligonukleotider for modulering av effektene av cytomegalovirusinfeksjoner | |
| EP1961826A3 (de) | Verfahren zur direkten Sequenzierung von Nukleinsäuren | |
| ATE419262T1 (de) | 2'-o-acetamido-modifizierte monomere und oligomere | |
| DE69331665D1 (de) | Methode zur behandlung von nukleinsäureproben | |
| DE69632466D1 (de) | Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen | |
| DE69627314D1 (de) | Kettenabbruchgruppen, ihre verwendung zur sequenzierung und synthese von nukleinsäuren und verfahren zu ihrer herstellung | |
| DE59611371D1 (de) | Verfahren zur Herstellung von Erythropoietin frei von tierischen Proteinen | |
| BR9307192A (pt) | Processo para determinar a sequência de nucleotídeos de um oligonucleotídeo de amostra | |
| DE3583564D1 (de) | Dna-sequenzen des ebv-genoms, rekombinante dna-molekuele, verfahren zur herstellung von ebv-verwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten. | |
| ATE258596T1 (de) | Antigens-nukleinsäure enthaltende pharmazeutische zusammensetzung zur verbeugung und/oder behandlung von neuronalen verletzungen, entartungen und zellentot, und zur behandlung von neoplasmen | |
| Atmadja et al. | The tertiary folding of Escherichia coli 16S RNA, as studied by in situ intra-RNA cross-linking of 30S ribosomal subunits with bis-(2-chloroethyI)-methylamine | |
| DE69638166D1 (de) | Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken | |
| ATE212382T1 (de) | Verfahren zur sequenzierung durch oligomerhybridisierung | |
| ATE443152T1 (de) | Verfahren und dns-konstrukte zur hemmung der genexpression in bakterien. | |
| UA43308C2 (uk) | Спосіб надання рослині резистентності до склеротиніозу | |
| RU2002109243A (ru) | Способ идентификации фармацевтических агентов из растительных экстрактов | |
| RU99111501A (ru) | Способ идентификации фармацевтических агентов из растительных экстрактов | |
| ATE108834T1 (de) | Spezifische nukleinsäurefragmente des menschlichen villingens, ihre anwendung für diagnostische zwecke. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |